Charles Schwab Investment Management Inc Relmada Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 12,505 shares of RLMD stock, worth $4,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,505

Previous 12,505 -0.0%

Holding current value

$4,501

Previous $37,000 8.11%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$2.22 - $3.54 $136,330 - $217,391	-61,410 Reduced 83.08%	12,505 $30,000
Q1 2023 May 11, 2023	BUY	$2.24 - $4.76 $28,011 - $59,523	12,505 Added 20.36%	73,915 $167,000
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $19,757 - $326,323	-9,105 Reduced 12.91%	61,410 $214,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $36,435 - $73,706	-1,991 Reduced 2.75%	70,515 $2.61 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $90,915 - $167,173	5,510 Added 8.22%	72,506 $1.38 Million
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $361,503 - $583,550	21,621 Added 47.65%	66,996 $1.81 Million
Q4 2021 Feb 11, 2022	BUY	$16.93 - $26.82 $69,717 - $110,444	4,118 Added 9.98%	45,375 $1.02 Million
Q3 2021 Nov 16, 2021	SELL	$21.86 - $34.77 $1.27 Million - $2.01 Million	-57,910 Reduced 58.4%	41,257 $1.08 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $136,077 - $180,285	4,605 Added 4.87%	99,167 $3.18 Million
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $54,655 - $68,111	1,734 Added 1.87%	94,562 $3.33 Million
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $101,352 - $135,001	3,392 Added 3.79%	92,828 $2.98 Million
Q3 2020 Nov 13, 2020	SELL	$34.42 - $43.78 $21,340 - $27,143	-620 Reduced 0.69%	89,436 $3.37 Million
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $1.16 Million - $1.84 Million	36,728 Added 68.87%	90,056 $4.03 Million
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $98,472 - $207,546	4,141 Added 8.42%	53,328 $1.82 Million
Q4 2019 Feb 07, 2020	BUY	$10.1 - $47.18 $496,788 - $2.32 Million	49,187 New	49,187 $1.92 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Relmada Therapeutics, Inc. Transaction History